Isatuximab and iberdomide for high-risk smoldering myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial is testing a combination of two drugs, isatuximab and iberdomide, to help people with high-risk smoldering myeloma avoid progressing to active multiple myeloma. It aims to see if this immunotherapy approach can delay or prevent the need for stronger treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have smoldering myeloma that is intermediate or high risk, diagnosed within the last 2 years, or upgraded to this risk level within the last 2 years.
- You must have measurable disease, such as a certain level of M-protein or free light chains in your blood or urine.
- You must have adequate organ function, including normal liver and kidney tests, and enough blood cell counts.
- You cannot have received any prior treatment for myeloma or smoldering myeloma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests iberdomide alone or with low-dose dexamethasone in people with intermediate- or high-risk “smoldering” multiple myeloma. The goal is to see if the treatment can control or delay progression to active myeloma.
This trial tests two immunotherapy drugs (teclistamab and daratumumab) for people with high-risk smoldering myeloma to see if the combination can stop or delay progression to active multiple myeloma. It's a new approach for those whose smoldering myeloma has a higher chance of becoming active.
This trial studies a precision approach to treat people with high-risk smoldering myeloma (a condition that can turn into active myeloma). The goal is to see whether the treatment can slow or prevent progression and improve outcomes.
This Phase 2 study tests a treatment approach for adults with active multiple myeloma (MM) or a high/intermediate-risk “smoldering” MM that hasn’t been treated yet. It may help by trying to control the disease earlier or more effectively, depending on what the trial drug(s) do.
This trial tests a new medicine called a BCMA/CD3 bispecific antibody for people with a very early form of multiple myeloma called high-risk smoldering myeloma. The goal is to see if this treatment can stop the disease from getting worse.
This trial watches people with a high-risk form of smoldering myeloma (an early, inactive stage of bone marrow cancer) to learn more about how it changes. It may help doctors know who needs treatment later.
Hear when a new Smouldering Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.